Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 17Carcinoma 5Neoplasm Metastasis 3Colonic Neoplasms 3Brain Neoplasms 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vipoma 1Recurrence 1Neuroendocrine Tumors 1Meningeal Carcinomatosis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms, Male 1Advanced Malignancies 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × epothilone B × Clear all
NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Novartis

Phase 2 Completed
33 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡